XIAP and lymphoma: While the above experiments indicate a role for XIAP in protecting newly EBV-infected cells from apoptosis, a subset of EBV+ B cells survive and can be immortalized, raising the question of why this does not apparently lead to lymphoma in patients with XLP-2.